In‑vivo CAR engineering reported

Chimeric antigen receptor T-cell therapy usually means taking a patient’s T cells out, rewriting them in a lab, and sending them back weeks later. A March 18 Nature paper reported a way to insert a full receptor gene into T cells inside the body instead. (nature.com) The team, led by William A. Nyberg, Pierre-Louis Bernard and colleagues, used two delivery systems: an enveloped delivery vehicle carrying CRISPR-Cas9 proteins and an adeno-associated virus carrying the DNA template for the new gene. The edit was designed to land in the T-cell receptor alpha constant, or TRAC, locus, a defined spot in the genome used to control receptor expression. (nature.com) In plain terms, the approach tries to build a cancer-hunting T cell without the usual custom manufacturing run. Standard care still relies on leukapheresis, cell activation, viral transduction, quality testing, freezing, and shipping, a chain that CancerNetwork said can take weeks and cost hundreds of thousands of dollars per patient. (cancernetwork.com) Nature said the edited cells reached “therapeutic levels” in humanized mouse models of B-cell aplasia, blood cancers, and solid tumors. The paper described stable, cell-specific expression after site-specific integration of a large DNA payload, rather than transient expression or random insertion. (nature.com) That distinction addresses a long-running problem in the field. CancerNetwork said earlier in-body approaches, including lentiviral delivery and lipid nanoparticle platforms, had shown feasibility in animals and entered a phase 1 trial, but durable, site-specific insertion of a full chimeric antigen receptor construct in vivo had remained out of reach. (cancernetwork.com) The paper arrived as in-vivo cell therapy moved from preclinical work into human testing. On March 25, Nature Medicine published a phase 1 study of ESO-T01, a lentiviral in-vivo anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma, reporting feasibility in five patients without dose-limiting toxicities. (nature.com) The new Nature study did not report a patient trial in its abstract; it reported in-vivo engineering at therapeutic levels in humanized mouse models. Cancer Discovery’s research news item called it the first report of therapeutic-level in-vivo engineered chimeric antigen receptor T cells against both blood and solid cancers using the two-vector system. (pubmed.ncbi.nlm.nih.gov) The delivery vehicle itself has been under development for more than a year. Berkeley researchers reported in February 2024 that antibody-targeted enveloped delivery vehicles could selectively edit human T cells in living animals, positioning the platform as a way to deliver CRISPR cargo to chosen blood-cell subsets. (news.berkeley.edu) Conventional chimeric antigen receptor T-cell therapy is already an established cancer treatment, with seven United States Food and Drug Administration-approved products listed by the agency and related FDA materials as of 2026. The practical bottleneck is not whether engineered T cells can work, but how fast and predictably they can be made for each patient. (fda.gov 1) (fda.gov 2) What comes next is the harder part: showing that targeted, in-body gene insertion can be repeated in patients with the same control seen in preclinical models. The field now has one March 2026 Nature paper on site-specific in-vivo engineering and one March 2026 Nature Medicine trial showing early clinical feasibility for a different in-vivo route. (nature.com 1) (nature.com 2)